151 related articles for article (PubMed ID: 16619108)
21. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
22. Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients?
Lala A; McLaughlin MA
Curr Hypertens Rep; 2008 Aug; 10(4):286-92. PubMed ID: 18625157
[TBL] [Abstract][Full Text] [Related]
23. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
Volpe M
QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
[TBL] [Abstract][Full Text] [Related]
24. The HOPE study: comparison with other trials of secondary prevention.
Otterstad JE; Sleight P
Eur Heart J; 2001 Aug; 22(15):1307-10. PubMed ID: 11465962
[No Abstract] [Full Text] [Related]
25. More than just hype.
Sigal RJ
CMAJ; 2003 Jun; 168(13):1647; author reply 1647-8. PubMed ID: 12821615
[No Abstract] [Full Text] [Related]
26. [Pathophysiological role of tissue renin-angiotensin-aldosterone system (RAAS) in human atherosclerosis].
Fukui K; Yamada H; Matsubara H
Nihon Rinsho; 2012 Sep; 70(9):1556-61. PubMed ID: 23012803
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
Burnier M; Waeber B; Hess O; Lüscher T
Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
[No Abstract] [Full Text] [Related]
28. Beta blockers and CVD protection: new frontiers.
Pancholia AK; Jain V
Indian Heart J; 2010; 62(2):99-100. PubMed ID: 21180297
[No Abstract] [Full Text] [Related]
29. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
Bommer WJ
Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
[TBL] [Abstract][Full Text] [Related]
30. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
31. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
Olsson AG
Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
[No Abstract] [Full Text] [Related]
32. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
33. [Clinical trials of renin-angiotensin antagonists in Japan].
Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):182-3. PubMed ID: 18421845
[No Abstract] [Full Text] [Related]
34. ACE inhibitors: back to prime time?
Gupta M; Verma S; Mancini GB
Heart; 2007 Sep; 93(9):1015-6. PubMed ID: 17699166
[No Abstract] [Full Text] [Related]
35. Diuretics are better first-line antihypertensive therapy than calcium channel blockers and ACE inhibitors.
Rollins G
Rep Med Guidel Outcomes Res; 2003 Jan; 14(2):5-7. PubMed ID: 12776699
[No Abstract] [Full Text] [Related]
36. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
Tocci G; Paneni F; Palano F; Sciarretta S; Ferrucci A; Kurtz T; Mancia G; Volpe M
Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
[TBL] [Abstract][Full Text] [Related]
37. ONTARGET still OFF-TARGET?
Lambers Heerspink HJ; de Zeeuw D
Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820
[No Abstract] [Full Text] [Related]
38. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
Asselbergs FW; van Gilst WH
Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
[TBL] [Abstract][Full Text] [Related]
39. Progression of cardiovascular damage: the role of renin-angiotensin system blockade.
Probstfield JL; O'Brien KD
Am J Cardiol; 2010 Jan; 105(1 Suppl):10A-20A. PubMed ID: 20102969
[TBL] [Abstract][Full Text] [Related]
40. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
Borghi C; Cosentino E; De Sanctis D
Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
